Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection : A Prospective Cohort Study
- PMID: 37399548
- PMCID: PMC10321467
- DOI: 10.7326/M23-0385
Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection : A Prospective Cohort Study
Abstract
Background: The performance of rapid antigen tests (Ag-RDTs) for screening asymptomatic and symptomatic persons for SARS-CoV-2 is not well established.
Objective: To evaluate the performance of Ag-RDTs for detection of SARS-CoV-2 among symptomatic and asymptomatic participants.
Design: This prospective cohort study enrolled participants between October 2021 and January 2022. Participants completed Ag-RDTs and reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 every 48 hours for 15 days.
Setting: Participants were enrolled digitally throughout the mainland United States. They self-collected anterior nasal swabs for Ag-RDTs and RT-PCR testing. Nasal swabs for RT-PCR were shipped to a central laboratory, whereas Ag-RDTs were done at home.
Participants: Of 7361 participants in the study, 5353 who were asymptomatic and negative for SARS-CoV-2 on study day 1 were eligible. In total, 154 participants had at least 1 positive RT-PCR result.
Measurements: The sensitivity of Ag-RDTs was measured on the basis of testing once (same-day), twice (after 48 hours), and thrice (after a total of 96 hours). The analysis was repeated for different days past index PCR positivity (DPIPPs) to approximate real-world scenarios where testing initiation may not always coincide with DPIPP 0. Results were stratified by symptom status.
Results: Among 154 participants who tested positive for SARS-CoV-2, 97 were asymptomatic and 57 had symptoms at infection onset. Serial testing with Ag-RDTs twice 48 hours apart resulted in an aggregated sensitivity of 93.4% (95% CI, 90.4% to 95.9%) among symptomatic participants on DPIPPs 0 to 6. When singleton positive results were excluded, the aggregated sensitivity on DPIPPs 0 to 6 for 2-time serial testing among asymptomatic participants was lower at 62.7% (CI, 57.0% to 70.5%), but it improved to 79.0% (CI, 70.1% to 87.4%) with testing 3 times at 48-hour intervals.
Limitation: Participants tested every 48 hours; therefore, these data cannot support conclusions about serial testing intervals shorter than 48 hours.
Conclusion: The performance of Ag-RDTs was optimized when asymptomatic participants tested 3 times at 48-hour intervals and when symptomatic participants tested 2 times separated by 48 hours.
Primary funding source: National Institutes of Health RADx Tech program.
Conflict of interest statement
Figures
Update of
-
Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection.medRxiv [Preprint]. 2023 Jan 23:2022.08.05.22278466. doi: 10.1101/2022.08.05.22278466. medRxiv. 2023. PMID: 35982680 Free PMC article. Updated. Preprint.
Similar articles
-
Comparison of Rapid Antigen Tests' Performance Between Delta and Omicron Variants of SARS-CoV-2 : A Secondary Analysis From a Serial Home Self-testing Study.Ann Intern Med. 2022 Dec;175(12):1685-1692. doi: 10.7326/M22-0760. Epub 2022 Oct 11. Ann Intern Med. 2022. PMID: 36215709 Free PMC article.
-
Performance of Rapid Antigen Tests to Detect Symptomatic and Asymptomatic SARS-CoV-2 Infection.medRxiv [Preprint]. 2023 Jan 23:2022.08.05.22278466. doi: 10.1101/2022.08.05.22278466. medRxiv. 2023. PMID: 35982680 Free PMC article. Updated. Preprint.
-
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article. Review.
-
A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.Trials. 2021 Jun 22;22(1):412. doi: 10.1186/s13063-021-05241-5. Trials. 2021. PMID: 34158099 Free PMC article.
-
Comparable performance of antigen-detecting rapid test by healthcare worker-collected and self-collected swabs for SARS-CoV-2 diagnostic: A systematic review and meta-analysis.Rev Med Virol. 2024 Jan;34(1):e2492. doi: 10.1002/rmv.2492. Epub 2023 Nov 21. Rev Med Virol. 2024. PMID: 37989714 Review.
Cited by
-
A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know.Antimicrob Steward Healthc Epidemiol. 2024 Jan 25;4(1):e8. doi: 10.1017/ash.2024.10. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 38415089 Free PMC article. Review.
-
Self-tests for COVID-19: What is the evidence? A living systematic review and meta-analysis (2020-2023).PLOS Glob Public Health. 2024 Feb 7;4(2):e0002336. doi: 10.1371/journal.pgph.0002336. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38324519 Free PMC article.
-
Development and Clinical Performance of InteliSwab® COVID-19 Rapid Test: Evaluation of Antigen Test for the Diagnosis of SARS-CoV-2 and Analytical Sensitivity to Detect Variants of Concern Including Omicron and Subvariants.Viruses. 2023 Dec 29;16(1):61. doi: 10.3390/v16010061. Viruses. 2023. PMID: 38257761 Free PMC article.
-
Evaluation of the analytical performance of the 15-minute point-of-care DASH™ SARS-CoV-2 RT-qPCR test.Diagn Microbiol Infect Dis. 2024 Jan;108(1):116120. doi: 10.1016/j.diagmicrobio.2023.116120. Epub 2023 Oct 21. Diagn Microbiol Infect Dis. 2024. PMID: 37898036
-
The Impact of Repeating COVID-19 Rapid Antigen Tests on Prevalence Boundary Performance and Missed Diagnoses.Diagnostics (Basel). 2023 Oct 16;13(20):3223. doi: 10.3390/diagnostics13203223. Diagnostics (Basel). 2023. PMID: 37892044 Free PMC article.
References
-
- Siddiqui ZK, Chaudhary M, Robinson ML, et al.; CONQUER COVID Consortium. Implementation and accuracy of BinaxNOW rapid antigen COVID-19 test in asymptomatic and symptomatic populations in a high-volume self-referred testing site. Microbiol Spectr. 2021;9:e0100821. [PMID: ] doi:10.1128/Spectrum.01008-21 - DOI - PMC - PubMed
-
- Prince-Guerra JL, Almendares O, Nolen LD, et al. Evaluation of Abbott BinaxNOW rapid antigen test for SARS-CoV-2 infection at two community-based testing sites — Pima County, Arizona, November 3-17, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:100-105. [PMID: ] doi:10.15585/mmwr.mm7003e3 - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous